X4 Pharmaceuticals: Promising Phase 2 Trial Results
Company Announcements

X4 Pharmaceuticals: Promising Phase 2 Trial Results

X4 Pharmaceuticals ( (XFOR) ) has shared an announcement.

X4 Pharmaceuticals has announced promising results from its Phase 2 trial of mavorixafor, an oral treatment for chronic neutropenia. The trial demonstrated that mavorixafor effectively increased mean absolute neutrophil counts (ANC) and allowed for reduced dosing of G-CSF while maintaining normal ANC levels. The findings, including enhanced neutrophil functionality, bolster confidence in the ongoing Phase 3 4WARD trial, offering hope for improved treatments for those with chronic neutropenia.

Find detailed analytics on XFOR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyX4 Pharmaceuticals reports Q3 EPS (18c), consensus (17c)
TheFlyX4 reports data from Phase 2 clinical trial evaluating mavorixafor
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App